SCHEMBL31677885

SCHEMBL31677885

CCc1c(C)c(=O)n2c(Br)c(C)nc2n1CC(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.43
▸ TRPA1 O75762 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ FPR1 P21462 1/20 0.39
▸ FPR2 P25090 1/20 0.39
▸ AKR1B1 P15121 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PTGDR2 Q9Y5Y4 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ AHR P35869 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ KCNJ5 P48544 1/20 0.38
▸ KCNJ3 P48549 1/20 0.38
▸ KAT2B Q92831 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31678760 0.85 KDM4E (0.43) KDM4ETRPA1MAPTFPR1FPR2
SCHEMBL31678252 0.85 KDM4E (0.40) KDM4ETRPA1MAPTFPR1FPR2
SCHEMBL31677892 0.83 KDM4E (0.43) KDM4ETRPA1MAPTFPR1FPR2
SCHEMBL31677815 0.83 KDM4E (0.40) KDM4ETRPA1MAPTFPR1FPR2
SCHEMBL31678122 0.82 KMT2A (0.38) KDM4EMAPTFPR1FPR2AKR1B1
SCHEMBL31678140 0.81 KDM4E (0.39) KDM4EMAPTAKR1B1KMT2AKDR
SCHEMBL31678761 0.79 MAPT (0.40) KDM4EMAPTAKR1B1KMT2ATP53
SCHEMBL31664578 0.77 KDM4E (0.43) KDM4ETRPA1MAPTFPR1FPR2
SCHEMBL31678008 0.77 KMT2A (0.45) KDM4EMAPTFPR1FPR2LMNA
SCHEMBL31678822 0.76 KDM4E (0.44) KDM4ETRPA1MAPTFPR1FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270218-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS INCYTE CORPORATION (US) 2025-08-28 — — US disclosed
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS INCYTE CORPORATION (US) 2025-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270217-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS WRN, RECQL, BLM KDM4E 2390/4885TRPA1 3835/4885MAPT 4647/4885
US-20250270218-A1 IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS WRN, RECQL, BLM KDM4E 3187/4885TRPA1 4243/4885MAPT 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback